PolyActiva Pty Ltd, a clinical-stage ophthalmology biopharmaceutical company, said it has successfully completed its phase 1 clinical study for its lead candidate, the Latanoprost FA SR Ocular Implant. The device was well tolerated in all 8 patients with no significant safety findings. The study also showed that the implant persists for the entire 6-month treatment period, after which the implant biodegrades completely over 6 weeks. This biodegradation profile should enable repeat dosing with the implant. The Latanoprost FA SR Ocular Implant is designed to eliminate eyedrop compliance issues by providing sustained treatment from a single implant administration over a 6-month period to treat glaucoma.